🇺🇸 FDA
Patent

US 9592304

Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors

granted A61KA61K38/00A61K47/6849

Quick answer

US patent 9592304 (Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K38/00, A61K47/6849, A61P, A61P35/00